Abstracts Archive - Page 76 of 2607 - ACR Meeting Abstracts

Abstract Number: 0169 • ACR Convergence 2025
The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment
Sally Wetten¹, George Mu², Keele E. Wurst³, Roger A. Levy⁴, Ben Newth⁵, Svetlana I. Nihtyanova⁶ and Elaine Irving⁷, ¹GSK, Epidemiology, Stevenage, United Kingdom, ²GSK, Statistics, Collegeville, PA, ³GSK, Immunology and Emerging Epidemiology, Durham, NC, ⁴GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁵GSK, Specialty Care, Global Medical Affairs, London, United Kingdom, ⁶GSK, Clinical Sciences, Research & Development, London, United Kingdom, ⁷GSK, Clinical, Stevenage, United Kingdom
Background/Purpose: Interstitial lung disease (ILD) is a serious pulmonary manifestation that can occur across all connective tissue disorders (CTD). Aberrant immune-mediated inflammation and fibrosis leads…
Abstract Number: 0241 • ACR Convergence 2025
Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review
Bercemhan Sulu¹, Sinem Nihal Esatoglu¹, Ibrahim Hatemi², Aykut Ferhat Celik³ and Gulen Hatemi¹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty / Department of Internal Medicine / Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are a key treatment modality for major organ involvement, one of the main contributors to morbidity and mortality, as…
Abstract Number: 0040 • ACR Convergence 2025
Identification Of A Novel, Expressed, Alternatively Spliced FCER1G Protein That Inhibits Receptor Function
Andrew Gibson¹, Jianming Wu², Chaoling Dong¹, R. Curtis Hendrickson¹, Travis Ptacek¹, Jeffrey Edberg¹ and Robert Kimberly¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Minnesota, Saint Paul, MN
Background/Purpose: The Tyrosine Activation Motif (ITAM)-containing FcRg chain, encoded by FCER1G, non-covalently couples with the immunoglobulin binding receptors, -- FcγRI (CD64), FcγRIIIa (CD16), and FcaRI…
Abstract Number: 0269 • ACR Convergence 2025
Clinical Landscape and Severity Markers of VEXAS Syndrome in a Spanish Cohort: Findings from VEXASSER Study Group
Paula García-Escudero¹, Marta López², Berta Magallares³, Dolly Viviana Fiallo Suárez⁴, Diego Dios Santos⁵, César Antonio Egües Dubuc⁶, Santos Castañeda⁷, Alicia Garcia⁸, Isla Morante Bolado⁹, Elena María Oliver García¹⁰, Clara Garcia Belando¹¹, Cristina Corrales¹², Francisco Javier Toyos¹³, Judit Font-Urgelles¹⁴, Meritxell Salles Lizarzaburu¹⁵, Carolina Merino¹⁶, Irene Carrion¹⁷, Jose Angel Hernandez¹⁸, Lourdes Villalobos¹⁹, Alina-Lucica Boteanu²⁰, Beatriz Frade Sosa²¹, cristiana Sieiro²², Irene Monjo Henry²³, Ernesto Trallero²⁴, Eugenia Enriquez²⁵, Maria Rodriguez²⁶, Elena Riera Alonso²⁷, Marta Ibañez²⁸, Delia Reina²⁹, Rafael Benito Melero González³⁰, Giuliano Boselli³¹, Alberto Mariano³², Ignacio Vázquez Gómez³³, Jose Alberto Miranda³⁴, Clara Moriano³⁵, Elena Aurrecoechea³⁶, Paloma Vela Casasempere³⁷, Iñigo Rúa-Figueroa³⁸ and Jaime Calvo³⁹, ¹Hospital Universitario Álava, Bilbao, Spain, ²Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ³Hospital de Sant Pau, Bareclona, ⁴H.U. Doctor Negrín, Gran Canarias, ⁵C. H. U. A Coruña, A Coruña, Spain, ⁶Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁷Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁸Rheumatologist, La Laguna, Spain, ⁹Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, ¹⁰H.C. U. Lozano Blesa, Zaragoza, ¹¹H.C. U. Virgen de la arrizaca, Murcia, ¹²HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA, Santander, Spain, ¹³Virgen Macarena University Hospital,, Sevilla, Spain, ¹⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁵Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain, ¹⁶Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain, ¹⁷Hospital del Mar, Barcelona, Spain, ¹⁸Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain, ¹⁹Ramon y Cajal Hospital, MADRID, Spain, ²⁰H.U. Ramón y Cajal, Madrid, Spain, ²¹Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²²Univrsity of Manchester, Manchester, United Kingdom, ²³Hospital Universitario La Paz, Madrid, Spain, ²⁴H. U. Vall d'Hebron, Barcelona, ²⁵Clínica Universidad de Navarra, Madrid, Spain, ²⁶H. Clínico San Carlos, Madrid, Spain, ²⁷Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ²⁸Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ²⁹Complex Hospitalari Moisès Broggi, Barcelona, Spain, ³⁰C. H. U. de Ourense, Ourense, ³¹Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ³²Virgen del Rocío University Hospital, Sevilla, Spain, ³³H.U. Doctor Peset, Valencia, ³⁴C. H. U. Lucus Augusti, Lugo, Spain, ³⁵Hospital León, LEON, Castilla y Leon, Spain, ³⁶H. Sierrallana, Santander, ³⁷Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ³⁸Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ³⁹Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain
Background/Purpose: VEXAS syndrome is a rare disease caused by somatic mutations in UBA1 gene. Different mutations in this gene appear to be associated with specific…
Abstract Number: 0163 • ACR Convergence 2025
Trends in hospitalization and outcomes among patients admitted with Adult-onset Still’s disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)
Mohammed Akram¹, Muhammad Sohaib Asghar², Woo Joo Lee², Basmah Fayaz Yousuf³, Carmen Tormo Carillo⁴ and Savier Aleman Rama⁴, ¹HCA Aventura, Aventura, FL, ²AdventHealth Sebring, Sebring, FL, ³SUNY Downstate Health Sciences University, New York, NY, ⁴HCA Florida Aventura Hospital, Aventura, FL
Background/Purpose: Adult-onset Still's Disease is a rare systemic autoinflammatory disorder characterized by spiking fever, arthralgia/arthritis, skin rash, and elevated inflammatory markers (ferritin). Estimated incidence ranges…
Abstract Number: 0095 • ACR Convergence 2025
Effect of JAK Inhibitors on Osteoblast Differentiation
Toshihiro Tanioka¹ and Takeo Isozaki², ¹Graduate School of Pharmacy, Showa Medical University, Shinagawa-ku,Tokyo, Tokyo, Japan, ²Graduate School of Pharmacy, Showa Medical University, Tokyo, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and joint destruction. Among the therapeutic strategies available, Janus kinase (JAK) inhibitors have…
Abstract Number: 0256 • ACR Convergence 2025
The Role of Extracorporeal Membrane Oxygenation in Cardiopulmonary Dysfunction Due to Rheumatologic Diseases: A Systematic Review
Kari Falaas¹, Lyubov Tiegs² and Elie Gertner³, ¹University of Minnesota, Minneapolis, ²University of Minnesota, Mineapolis, ³Regions Hospital, St. Paul, MN
Background/Purpose: Rheumatologists are increasingly involved in the management of patients with severe manifestations of rheumatologic disease treated with Extracorporeal Membrane Oxygenation (ECMO). A 2020 systematic…
Abstract Number: 0068 • ACR Convergence 2025
Unique Fibroblast-like Synoviocyte Phenotype with Elevated MCSF Expression Induced by TLR5 Activation in Rheumatoid Arthritis
Aryan Patel¹, Osama Al Zoubi² and Shiva Shahrara³, ¹University of Illinois at Chicago, Chicago, ²University of Illinois at Chicago, Chicago, IL, ³University of Illinois, Chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1% of the global population, causing significant morbidity and disability. Fibroblast-like synoviocytes (FLS) are…
Abstract Number: 0270 • ACR Convergence 2025
Diagnostic Challenge of IgG4-related Disease: Comparison Between ACR/EULAR, Umehara, and Okazaki Criteria
Rafael Gálvez Sánchez¹, Ivan Ferraz Amaro², Fernando Lopez Gutierrez³, Javier Loricera⁴, Pablo Martínez Calabuig⁵, Jorge Juan Fragío Gil⁶, Roxana González Mazarí⁷, Cristina Hormigos Martín⁸, DALIFER FREITES⁹, Maria Rodríguez Laguna⁸, Patricia Moya Alvarado¹⁰, Marta López I Gómez¹¹, Hector Corominas Macia¹⁰, Maite Silva Díaz¹², Guillermo González Arribas¹², Angel García Aparicio¹³, Judit Font-Urgelles¹⁴, Ivette Casafont Solé¹⁵, Elisabet Castaneda¹⁶, Carolina Merino Argumánez¹⁷, Raquel Zas Vaamonde¹⁸, Juan Molina Collada¹⁹, Sergio Rodríguez Montero²⁰, Rafael Melero Gonzalez²¹, Eva Galíndez Agirregoikoa²², Andrea Hernández²³, Lucia Pantoja Zarza²⁴, Ignacio Braña Abascal²⁵, Vega Jovaní²⁶, Elia Valls Pascual²⁷, Natalia Mena Vázquez²⁸, ADELA MARIA GALLEGO FLORES²⁹, Noelia Cabaleiro Raña³⁰, Raúl Veroz González³¹, Mariano Andrés³², Santos Castañeda Sainz³³ and Ricardo Blanco³⁴, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Hospital Universitario Marqués de Valdecilla, Immunopathology Group -IDIVAL, Reumatología, Santander, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁵Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ⁶Hospital General Universitario, Valencia, Spain, ⁷Hospital General Universitario de Valencia, Reumatología, Valencia, Valencia, Spain, ⁸Hospital Clínico San Carlos, Reumatología, Madrid, Madrid, Spain, ⁹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ¹⁰Hospital de Sant Pau, Reumatología, Barcelona, Barcelona, Spain, ¹¹Hospital Universitario de Araba, Reumatología, Vitoria,, Vitoria, Spain, ¹²Complejo Hospitalario Universitario de A Coruña, Reumatología, A Coruña, Spain, ¹³Hospital Universitario de Toledo, Reumatología, Toledo, Toledo, Spain, ¹⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁵Hospital German Trias i Pujol, Reumatología, Badalona, Badalona, Spain, ¹⁶Hospital Universitario Infanta Sofía, Reumatología, Madrid, Madrid, Spain, ¹⁷Hospital Universitario Puerta del Hierro, Reumatología, Madrid, Madrid, Spain, ¹⁸Hospital Universitario ¹² de Octubre, Reumatología, Madrid, Madrid, Spain, ¹⁹Hospital General Universitario Gregorio Marañón, Reumatología, Madrid, Madrid, Spain, ²⁰Hospital Universitario de Valme, Reumatología, Sevilla, Sevilla, Spain, ²¹Hospital Alvaro Cunqueiro, Reumatología, Vigo, Vigo, Spain, ²²BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ²³Hospital Universitario de Gran Canaria Dr Negrin, Reumatología, Palmas de Gran Canaria, Gran Canaria, Spain, ²⁴Hospital General de Segovia, Reumatología, Segovia, Segovia, Spain, ²⁵Hospital Universitario Central de Asturias, Reumatología, Oviedo, Oviedo, Spain, ²⁶Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ²⁷Hospital General de Valencia, Reumatología, Valencia, Valencia, Spain, ²⁸Hospital Regional Universitario de Málaga, Reumatología, Málaga, Malaga, Spain, ²⁹Complejo Hospitalario don Benito Villanueva, Reumatología, Badajoz, Badajoz, Extremadura, Spain, ³⁰Hospital Universitario Montecelo, Reumatología, Pontevedra, Pontevedra, Spain, ³¹Hospital de Mérida, Reumatología, Mérida, Mérida, Spain, ³²Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Spain, ³³Hospital Universitario La Princesa, Reumatología, Madrid Grupo de cooperación nacional de enfermedad relacionada con IgG⁴: Blanca García Magallón (Hospital Universitario Puerta del Hierro), Maite Odriozola Gil (Hospital Universitario de Valme), Cristina Arciniega (Hospital de Mérida), Maria Lourdes Mateo Soria (Hospital German Trias i Pujol), Santiago Muñoz (Hospital Universitario Infanta Sofía), Iñigo Jesús Rua Figueroa, (Hospital Universitario de Gran Canaria Dr Negrin), Sabela Fernández Aguado, (Hospital de Montecelo)., Madrid, Spain, ³⁴Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgG4-related disease (IgG4-RD) is a rare immune-mediated condition characterized by fibro-sclerosing inflammation, elevated serum and tissue IgG4 levels, and heterogeneous clinical manifestations. Several classification…
Abstract Number: 0221 • ACR Convergence 2025
A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-Centered National Rheumatoid Arthritis Network
Grant Cannon¹, Beth Wallace², Deana Lazaro³, Pascale Schwab⁴, Paul Monach⁵, Ankoor Shah⁶, Gail Kerr⁷, Andreas Reimold⁸, Joshua Baker⁹, Gary Kunkel¹⁰, Katherine Wysham¹¹, Liron Caplan¹², John Richards¹³, Aleksander Lenert¹⁴, Andrew Jones¹⁵, Ted Mikuls¹⁶, Maria I. ("Maio") Danila¹⁷, Bryant England¹⁶, Brian Sauer¹⁸, Jorge Rojas¹⁹ and Isaac Smith²⁰, ¹University of Utah and Salt Lake City VA, Salt Lake City, UT, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³VA New York Harbor Healthcare system, Short Hills, NJ, ⁴VA Portland and Oregon Health & Science University, Portland, OR, ⁵VA Boston Healthcare System, Boston, MA, ⁶Duke University, Durham, NC, ⁷Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁸Dallas VA Medical Center, Dallas, TX, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ¹²Rocky Mountain Regional VAMC, Aurora, CO, ¹³Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁴University of Iowa, Iowa City, IA, ¹⁵VA Saint Louis and Washington University, Saint Louis, ¹⁶University of Nebraska Medical Center, Omaha, NE, ¹⁷University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁸Salt Lake City VA/University of Utah, Salt Lake City, UT, ¹⁹VA Puget Sound Health Care System, Seattle, WA, ²⁰Duke University Hospital, Durham, NC
Background/Purpose: Clinical guidelines recommend the use of disease activity measures (DAMs) in rheumatoid arthritis (RA) management. Measurement of DAMs is also a critical component of…
Abstract Number: 0002 • ACR Convergence 2025
KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
Brian Kim, Christine Lowe, Francisco Flores, Jeremy Margaitis, Alessandro Calo, Stacey Valny, Anna Konecny, Eva Jaghatspanyan, Sean Yoder, Kenneth Ertel, Simone Filosto, Jodi Murakami and David Barrett, Kite, a Gilead Company, Santa Monica, CA
Background/Purpose: B-cell dysregulation is a key factor in the development and progression of autoimmune diseases, and B-cell inhibition has been a cornerstone of treatment for…
Abstract Number: 0178 • ACR Convergence 2025
Prevalence and factors associated with virtual rheumatology care utilization in a national population of Veterans with RA
Beth Wallace¹, Yuqing Gao², Shirley Cohen-Mekelburg² and Akbar Waljee², ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²VA Ann Arbor Healthcare Center, Ann Arbor
Background/Purpose: Up to half of RA patients receive virtual rheumatology care, which is associated with high satisfaction but potentially lower quality. We aimed to identify…
Abstract Number: 0028 • ACR Convergence 2025
Computational and Laboratory Identification of Risk-Driving Alleles on Juvenile Idiopathic Arthritis (JIA)-Associated Haplotypes
Adam He¹, Hannah Ainsworth², Kaiyu Jiang³, Ekaterina Khtovatkova², Yanmin Chen³, Carl Langefeld⁴, Charles G Danko¹ and James N. Jarvis⁵, ¹Cornell University Baker School of Veterinary Medicine, Ithaca, NY, ²Wake Forest University, Winston-Salem, NC, ³University of Washington School of Medicine, Seattle, WA, ⁴Wake Forest University School of Medicine, Winston Salem, NC, ⁵University of Washington Center for Indigenous Health, Seattle, WA
Background/Purpose: Multiple genomic regions are known to confer risk for JIA. However, identifying the SNPs that exert the biological effects that confer risk, and therefore…
Abstract Number: 0297 • ACR Convergence 2025
Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis
Natasha Le Blanc¹, Marie Hudson¹, Ana Cristina Gonzalez Sanchez², Lina Marcela Diaz Gallo² and Valerie Leclair³, ¹McGill University, Montréal, QC, Canada, ²Karolinska Institutet, Stockholm, Sweden, ³McGill University, Montréal, Canada
Background/Purpose: Dermatomyositis (DM) is a multisystemic immune mediated disease presenting with heterogeneous clinical features. Disease monitoring in DM relies in part on biomarkers of muscle…
Abstract Number: 0271 • ACR Convergence 2025
Clinical Presentation of Igg4-Related Disease. Multicenter Study and Literature Review
Rafael Gálvez Sánchez¹, Fernando Lopez Gutierrez², Javier Loricera³, Pablo Martínez Calabuig⁴, Jorge Juan Fragío Gil⁵, Roxana González Mazario⁶, Cristina Hormigos Martin⁷, DALIFER FREITES⁸, Maria Rodriguez Laguna⁹, Patricia Moya Albarado¹⁰, Marta López i Gómez¹¹, Hector Corominas¹², Maite Silva-Diaz¹³, GUILLERMO GONZALEZ ARRIBAS¹⁴, Angel Garcia-Aparicio¹⁵, Judit Font-Urgelles¹⁶, Ivette Casafont-Solé¹⁶, elisabeth Castañeda¹⁷, Carolina Merino¹⁸, Raquel Zas¹⁹, Juan Molina-Collada²⁰, Sergio Rodríguez Montero²¹, Rafael B. Melero-González²², Eva Galíndez Agirregoikoa²³, Andrea Hernández²⁴, Lucia Pantoja²⁵, Ignacio Braña²⁶, Vega Jovaní²⁷, Elia Valls-Pascual²⁸, Natalia Mena Vázquez²⁹, Adela Gallego³⁰, Noelia Cabaleiro Raña³¹, Raul Veroz³², Mariano Andrés Collado³³, Santos Castañeda³⁴ and Ricardo Blanco³⁵, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Immunopathology Group -IDIVAL, Reumatología, Santander, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ⁵Hospital General Universitario, Valencia, Spain, ⁶Hospital General de Valencia, Valencia, Spain, ⁷Hospital Clínico San Carlos, Madrid, Spain, ⁸Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁹Hospital Clinico San Carlos, Madrid, Spain, ¹⁰Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹¹Hospital Universitario de Araba, Vitoria, Pais Vasco, Spain, ¹²Hospital de Sant Pau, Barcelona, Spain, ¹³Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ¹⁴Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ¹⁵Hospital Universitario de Toledo, Toledo, Spain, ¹⁶Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁷Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ¹⁸Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain, ¹⁹Hospital Universitario Doce de Octubre, Madrid, Spain, ²⁰Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Spain, ²¹Hospital Universitario de Valme, Sevilla, Andalucia, Spain, ²²COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ²³BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ²⁴Hospital Universitario de Gran Canaria Dr Negrin, Palmas de Gran Canaria, Canarias, Spain, ²⁵Complejo Hospitalario Segovia, Segovia, Spain, ²⁶Hospital Universitario Central de Asturias, Oviedo, Spain, ²⁷Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ²⁸Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ²⁹Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ³⁰Complejo Hospitalario don Benito Villanueva, Badajoz, Spain, ³¹Hospital Universitario Montecelo, Rheumatology, Pontevedra, Galicia, Spain, ³²Hospital de Merida, Merida, Extremadura, Spain, ³³Hospital General Universitario de Alicante, Madrid, Comunidad Valenciana, Spain, ³⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ³⁵Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory entity that can involve almost every organ, with characteristic histological features. Its pathogenesis remains poorly understood, clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].